NCT05155332 2026-03-17A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)Boehringer IngelheimPhase 1 Recruiting190 enrolled